Australia vs Singapore: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Australia
0.1%
in 2024
Singapore
0.1%
in 2024
Australia rank
112th
Singapore rank
112th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Australia
- Singapore
How they compare
Australia currently reports 0.1% against 0.1% in Singapore, a difference of 0.0%.
Across all 10 years both countries report, Singapore has been ahead every year.
Australia ranks 112th and Singapore ranks 112th of 215 countries.
Singapore has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Australia | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Singapore |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Australia or Singapore?
- Australia, at 0.1% against 0.1% in Singapore as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Australia and Singapore?
- 0.0%, with Australia ahead.
- How many years of comparable data are there for Australia and Singapore?
- 10 years are reported by both, from 2015 to 2024.
- How do Australia and Singapore rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Australia ranks 112th and Singapore ranks 112th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.